IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Clinical Trial ID NCT01265901

PubWeight™ 26.63‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01265901

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012 5.44
2 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
3 IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2016 1.42
4 Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 2014 1.11
5 Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol 2013 1.05
6 Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol 2013 0.98
7 Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer 2014 0.93
8 Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014 0.89
9 Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 2016 0.84
10 Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014 0.84
11 Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015 0.83
12 Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther 2014 0.82
13 A new age for vaccine therapy in renal cell carcinoma. Cancer J 2013 0.81
14 Comparing comparators: a look at control arms in kidney cancer studies over the years. Br J Cancer 2014 0.81
15 Therapeutic challenges in renal cell carcinoma. Am J Clin Exp Urol 2015 0.80
16 Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc 2015 0.78
17 Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4. Front Oncol 2013 0.78
18 Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology 2015 0.77
19 Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol 2015 0.77
20 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
21 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
22 An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res 2015 0.76
23 A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position. Clin Genitourin Cancer 2012 0.75
24 Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014 0.75
Next 100